根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所股票上市规则》以及《北京同仁堂股份有限公司章程》等有关规定，作为北 京同仁堂股份有限公司（以下简称公司）的独立董事，我们对公司第十届董事会 独立董事 2024 年第一次专门会议审议的《控股股东关于解决和避免与公司同业 竞争承诺函的预案》，发表如下意见： 控股股东中国北京同仁堂（集团）有限责任公司出具的《关于解决和避免与 北京同仁堂股份有限公司同业竞争的承诺函》符合《上市公司监管指引第 4 号 ——上市公司及其相关方承诺》等相关法律、法规的规定，有利于保护公司和全 体股东的利益；同意将该预案提交董事会表决，同意相关预案经董事会关联董事 回避表决并审议通过后，提请公司股东大会审议。 北京同仁堂股份有限公司 北京同仁堂股份有限公司独立董事专门会议 关于《控股股东关于解决和避免与公司同业竞争承诺函的预案》的审核意见 独立董事：乔延江、王桂华、王钊、杨庆英 2024 年 12 月 18 日 ...

Group 1: Product Strategy - The company has launched the "Royal Medicine Legend Series" as a premium product line, with initial sales meeting expectations in key provinces and cities [2] - The premium product series is currently in an exploratory phase, contributing a small proportion to overall business scale [2] - The company plans to introduce a second batch of premium products based on market feedback to meet diverse consumer needs [2] Group 2: Market Reach and Distribution - The company is enhancing its marketing reform by strengthening its own channel construction and gradually expanding retail stores to increase brand awareness [2][4] - A comprehensive distribution system is being established nationwide, including provincial distribution centers to support terminal sales [2][4] - Collaboration with large chains and social pharmacies is being pursued to create dedicated product displays, enriching the product variety available to consumers [4] Group 3: Sales Performance and Marketing Effectiveness - The market sales of the "An Gong Niu Huang Wan" product are meeting expectations, with a focus on promoting major product categories [4] - The company is implementing a differentiated marketing strategy for the "Royal Medicine Legend Series" and "Royal Medicine 300 Series" to enhance brand influence [4] - Continuous marketing reforms are being pursued to integrate marketing systems and improve service quality at retail outlets [4] Group 4: Medical Business Development - The company has established a medical division to expand its medical market presence, leveraging a diverse product range included in the national essential drug list [4] - Efforts include organizing academic exchange meetings and clinical evidence-based medicine verification to support medical channel development [4] Group 5: Overall Business Strategy - The company is committed to a long-term development strategy, focusing on production stability, channel construction, and market sales to promote high-quality operational growth [4]

证券代码：600085 证券简称：同仁堂 公告编号：2024-033 北京同仁堂股份有限公司 上述高级管理人员最近三年不存在受到中国证券监督管理委员会、证券交易 所及其他部门行政处罚的情形，其任职资格符合相关法律、法规和《北京同仁堂 股份有限公司章程》等有关规定，不存在相关法律、法规和《北京同仁堂股份有 限公司章程》规定的不得担任上市公司高级管理人员的情形。 二、 关于公司高级管理人员辞任的情况 公司收到杨利先生提交的辞任函，因工作调整原因，杨利先生辞任公司副总 经理职务，其辞任函自送达公司及董事会之日起生效，杨利先生辞任公司副总经 理职务后，将继续担任公司董事职务，并在公司控股子公司北京同仁堂科技发展 股份有限公司担任副总经理职务。 杨利先生担任公司副总经理期间认真履职、勤勉尽责，公司及董事会对杨利 先生在任职期间为公司做出贡献表示衷心感谢。 特此公告。 关于部分高级管理人员调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京同仁堂股份有限公司（以下简称公司）于 2024 年 11 月 28 日召开第十届 董事会 ...

证券代码：600085 证券简称：同仁堂 公告编号：2024-034 北京同仁堂股份有限公司 关于获得加拿大产品许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京同仁堂股份有限公司（以下简称公司）分支机构北京同仁堂股份有限公 司同仁堂制药厂（以下简称同仁堂制药厂）收到加拿大卫生部核准签发的《产品 许可证（三类）》，同仁堂制药厂产品时疫清瘟丸获得加拿大产品注册。公司现将 有关情况公告如下： 产品名称 品种批准文 号（NPN） 剂型 适应症 持证商 名称 持证商地址 时疫清瘟丸 80133572 丸剂 1.基于传统中医中 药理论的药物/产品 /制剂。 2.传统中药用于清 热透表，解热毒。 3.传统中药用于头 疼身痛，恶寒发热， 四肢倦怠，喉痛咽 干，痄腮红肿。 4.传统中药用于外 感季节性病毒性流 感症状。 北京同 仁堂股 份有限 公司同 仁堂制 药厂 北京市大兴 区中关村科 技园区大兴 生物医药产 业基地天贵 大街 33 号 一、 产品注册许可基本情况 求，完成包括但不限于对生产场地的加拿大生产质量体系认证等行政 ...

关 于 北 京 同 仁 堂 股 份 有 限 公 司 2 024 年 第 二 次 临 时 股 东 大 会 的 法 律 意 见 书 北 京 大 成 律 师 事 务 所 大成证字[2024]第 207 号 北 京 大 成 律 师 事 务 所 www.dentons.cn 北京市朝阳区朝阳门南大街 10 号兆泰国际中心 B 座 16-21 层（100020） ZT International Center, No.10, Chaoyangmen Nandajie, Dongdaqiao Road Chaoyang District, 100020, Beijing, China Tel:+8610-58137799 Fax:+8610-58137788 北京大成律师事务所 关于北京同仁堂股份有限公司 2024 年第二次临时股东大会的法律意见书 致：北京同仁堂股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和 国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司股东 大会规则（2022 年修订）》（以下简称"《股东大会规则》"）等法律、法规和其他 有关规范性文件的要求 ...

证券代码：600085 证券简称：同仁堂 公告编号：2024-032 北京同仁堂股份有限公司 2024 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2024 年 11 月 15 日 (二) 股东大会召开的地点：北京市东城区崇外大街 42 号同仁堂大厦 5 层会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,249 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 735,784,363 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 53.6493 | | 总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长邸淑兵先生主持。会议采用现场投 票和网络投票相结合的表决方式进行表决。会议的召 ...

Core Viewpoint - Beijing Tongrentang (Fujian) Pharmaceutical Co., Ltd. has been established with a registered capital of 30 million yuan, indicating an expansion of the Tongrentang brand in the pharmaceutical sector [1] Company Summary - The legal representative of the newly established company is Li Shuo [1] - The registered capital of the company is 30 million yuan [1] - The business scope includes drug wholesale, drug retail, food sales, third-class medical device operations, first-class medical device sales, agricultural and sideline product sales, and the purchase and sale of real estate Chinese herbal medicine (excluding Chinese medicine pieces) [1] - The company is jointly held by Beijing Tongrentang Commercial Investment Group Co., Ltd. and Fujian Kangcheng Pharmaceutical Co., Ltd. [1]

Investment Rating - The report maintains a "Recommend" rating for Tongrentang (600085) with a target price of 50.4 RMB, compared to the current price of 40.40 RMB [1] Core Views - Tongrentang achieved steady revenue growth but faced cost pressures in 1-3Q24, with revenue of 13.82 billion RMB (+0.7% YoY) and net profit of 1.35 billion RMB (-3% YoY) [1] - The company's subsidiaries showed mixed performance: the pharmaceutical segment remained stable, while the commercial and traditional medicine segments were under pressure [1] - The report expects Tongrentang's net profit to grow at a CAGR of 15% from 2024 to 2026, reaching 2.28 billion RMB by 2026 [1] Financial Performance - 3Q24 revenue was 4.06 billion RMB (+2.4% YoY), with net profit declining 19% YoY to 330 million RMB due to gross margin pressure and increased operating expenses [1] - Gross margin in 3Q24 decreased by 3.5 percentage points YoY, with net profit margin down 4 percentage points [1] - Accounts receivable increased to 1.59 billion RMB in 3Q24, while contract liabilities slightly decreased to 470 million RMB [1] Subsidiary Performance - Tongrentang Technology reported 1-3Q24 revenue of 5.48 billion RMB (+2.7% YoY) and net profit of 550 million RMB (+6.3% YoY), with gross margin declining 3 percentage points to 39.7% [1] - The commercial group was affected by weak consumer demand and policy changes [1] Valuation and Projections - The report forecasts 2024-2026 revenue of 18.23/20.43/22.89 billion RMB, with YoY growth rates of 2.1%/12.1%/12.1% [2] - Net profit is projected to reach 1.72/1.98/2.28 billion RMB in 2024-2026, with EPS of 1.25/1.44/1.66 RMB [2] - The target PE ratio of 35x for 2025 implies a target price of 50.4 RMB [1] Industry Context - The report focuses on the traditional Chinese medicine sector, where Tongrentang is a leading player [3] - The company's performance is analyzed in the context of broader market trends and consumer demand patterns [1] Historical Performance - In 2023, Tongrentang achieved revenue of 17.86 billion RMB (+16.2% YoY) and net profit of 1.67 billion RMB (+17.0% YoY) [2] - The company's 12-month stock price range was 31.21-54.90 RMB, with a current market capitalization of 55.41 billion RMB [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600085 证券简称：同仁堂 公告编号：2024-031 北京同仁堂股份有限公司 关于获得加拿大产品许可证的公告 二、 对公司的影响及风险提示 同仁堂制药厂养阴清肺丸取得加拿大卫生部颁发的《产品许可证（三类）》 系产品上市许可。该产品若拟在加拿大销售，后续还需根据加拿大卫生部法规要 求，完成包括但不限于对生产场地的加拿大生产质量体系认证等行政审批事项， 该等审批可能存在一定不确定性。本次获批事宜对公司近期经营业绩不会产生重 大影响。 1 北京同仁堂股份有限公司董事会 2024 年 11 月 1 日 北京同仁堂股份有限公司（以下简称公司）分支机构北京同仁堂股份有限公 司同仁堂制药厂（以下简称同仁堂制药厂）收到加拿大卫生部核准签发的《产品 许可证（三类）》，同仁堂制药厂产品养阴清肺丸获得加拿大产品注册。公司现将 有关情况公告如下： 截止本公告日，同仁堂制药厂就上述产品研发投入累计约 100 万元（金额未 经审计）。 产品名称 品种批准文 号（NPN） 剂型 适应症 持证商 ...

Revenue and Profit Performance - Revenue for the third quarter reached RMB 4.06 billion, a year-on-year increase of 2.42%[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 329.09 million, a year-on-year decrease of 18.57%[2] - Total revenue from the beginning of the year to the end of the reporting period was RMB 13.82 billion, a year-on-year increase of 0.72%[4] - Net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period was RMB 1.35 billion, a year-on-year decrease of 2.92%[4] - Total revenue for the first three quarters of 2024 reached 13.82 billion RMB, a slight increase from 13.72 billion RMB in the same period of 2023[17] - Net profit for the first three quarters of 2024 was 2.34 billion RMB, compared to 2.63 billion RMB in 2023[17] - Net profit attributable to parent company shareholders decreased to 1.35 billion yuan from 1.39 billion yuan, with minority shareholders' profit also dropping to 633.60 million yuan from 782.62 million yuan[19] - Total comprehensive income decreased to 1.97 billion yuan from 2.26 billion yuan, with parent company owners' share at 1.34 billion yuan and minority shareholders' share at 627.00 million yuan[20] - Basic earnings per share decreased to 0.984 yuan from 1.014 yuan[20] Asset and Liability Changes - Total assets as of the end of the reporting period were RMB 31.24 billion, a year-on-year increase of 3.82%[3] - Equity attributable to shareholders of the listed company as of the end of the reporting period was RMB 12.98 billion, a year-on-year decrease of 0.61%[3] - Total assets as of September 30, 2024, stood at 31.24 billion RMB, up from 30.09 billion RMB at the end of 2023[16] - Total liabilities as of September 30, 2024, were 10.73 billion RMB, compared to 9.83 billion RMB at the end of 2023[16] - Cash and cash equivalents decreased to 10.94 billion RMB as of September 30, 2024, from 12.13 billion RMB at the end of 2023[14] - Accounts receivable increased to 1.59 billion RMB as of September 30, 2024, from 1.06 billion RMB at the end of 2023[14] - Inventory rose to 10.79 billion RMB as of September 30, 2024, from 9.34 billion RMB at the end of 2023[14] - Long-term investments increased to 76.53 million RMB as of September 30, 2024, from 18.24 million RMB at the end of 2023[14] - Ending cash and cash equivalents balance decreased to 10.89 billion yuan from 12.82 billion yuan[22] Shareholder and Investment Information - The largest shareholder is China Beijing Tongrentang (Group) Co., Ltd., holding 719,308,540 shares, accounting for a significant portion of the total shares[9] - China Securities Finance Corporation holds 41,033,808 shares, representing a notable stake in the company[9] - Hong Kong Securities Clearing Company Limited holds 32,871,772 shares, indicating substantial foreign investment[9] - The top 10 shareholders collectively hold a significant portion of the company's shares, with no known relationships or concerted actions among them[9] - The company's shares are widely held by various funds, including the China Industrial and Commercial Bank Co., Ltd. - China Europe Medical Health Fund, holding 39,610,214 shares[9] - The company's shares are also held by major index funds such as the China Construction Bank Co., Ltd. - E Fund CSI 300 Healthcare ETF, holding 10,709,993 shares[11] - The company's shares are actively traded, with significant holdings by funds like the China Industrial and Commercial Bank Co., Ltd. - Huaxia CSI 300 ETF, holding 5,529,476 shares[11] - The company's shares are also held by the China Bank Co., Ltd. - Harvest CSI 300 ETF, holding 5,368,456 shares[11] - The company's shares are subject to margin trading and securities lending, with some shareholders participating in these activities[10] - The company's shares are held by a diverse group of investors, including both domestic and international entities, indicating broad market interest[12] Cost and Expense Analysis - The decrease in net profit was mainly due to the increase in raw material costs, particularly the rise in prices of traditional Chinese medicinal materials[4] - Operating costs for the first three quarters of 2024 were 11.48 billion RMB, up from 11.09 billion RMB in 2023[17] - Research and development expenses for the first three quarters of 2024 were 139.09 million RMB, down from 150.40 million RMB in 2023[17] - Interest expenses increased to 97.54 million yuan from 66.11 million yuan, while interest income decreased to 124.54 million yuan from 158.29 million yuan[19] - Other income rose significantly to 81.76 million yuan from 25.58 million yuan, and investment income turned positive at 66.37 million yuan compared to a loss of 1.05 million yuan[19] Cash Flow and Financial Activities - Cash flow from operating activities turned negative at -52.55 million yuan, compared to a positive 2.39 billion yuan in the previous year[21] - Cash flow from investing activities worsened to -223.42 million yuan from -83.07 million yuan[22] - Cash flow from financing activities improved slightly to -846.47 million yuan from -1.17 billion yuan[22] - Net increase in cash and cash equivalents was -1.13 billion yuan, a significant decrease from the previous year's 1.19 billion yuan increase[22] Other Financial Metrics - Accounts receivable increased by 50.64% compared to the beginning of the year, mainly due to the rolling use of customer credit limits[6] - Long-term equity investments increased by 319.49% compared to the beginning of the year, primarily due to the transfer of shares in a subsidiary[7] - Other income increased by 219.61% year-on-year, mainly due to the recognition of additional tax deductions for advanced manufacturing enterprises[7]